Boston Scientific Enters U.S. Atrial Flutter Market With EPT-1000 XP
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific aims to carve out a leading share of the estimated $50-$60 mil. worldwide atrial flutter market opportunity with the EPT-1000 XP cardiac ablation system, the firm says